
|Videos|December 22, 2017
Dr. Wang Discusses Acalabrutinib in MCL
Author(s)Michael Wang, MD
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.
Advertisement
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).
Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.
Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































